Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Meanwhile, Novo Nordisk announced plans to invest $556 million to expand its Tianjin city production facility.

KBP Biosciences sold global rights for its hypertension candidate to Novo Nordisk in an agreement worth up to $1.3 billion. Also, EpimAb Bio sold the rights to use its Fabs-In-Tandem Immunoglobulin platform to Almirall in a $210 million agreement.

Deals and financings, trials and approvals in the Chinese biotech/biopharma sphere.

WuXi Biologics out-licensed global rights for up to four pre-clinical bi- & multi-specific TCE antibodies to GSK in a $1.5 billion agreement. WuXi Biologics will receive $40 million upfront and up to $1.46 billion in milestones, plus royalties.

As a CXO giant listed in Hong Kong, Wuxi Biologics will be removed from the list eight months after it was added to the ‘Unverified list’ of the Bureau of Industry and Security on Feb. 7, 2022, according to the new revisions.